Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 8-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Paroxetine (20 mg q24) as Positive Control, Evaluating the Efficacy and Safety of 2 Fixed Doses of SR58611A (175 mg q12 and 350 mg q12) in Outpatients With GAD

NCT00332891 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00332891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00332891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 8-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Paroxetine (20 mg q24) as Positive Control, Evaluating the Efficacy and Safety of 2 Fixed Doses of SR58611A (175 mg q12 and 350 mg q12) in Outpatients With GAD
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2006
Completion date
April 30, 2007
Enrollment
508 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

anxiety disorders